男性性腺功能低下市場機會、成長動力、產業趨勢分析及預測（2025-2034）

2024 年全球男性性腺功能低下市場價值為 40 億美元，預計 2025 年至 2034 年的複合年成長率為 5.2%。成長的動力來自於人們對荷爾蒙失衡認知的提高、診斷能力的進步以及睪固酮缺乏症盛行率的上升。當身體無法產生足夠的睪固酮或睪丸功能不正常時，就會出現這種情況，導致嚴重的身體、性和心理併發症。由於睪固酮在許多男性生理功能中發揮著至關重要的作用，其缺乏會對整體健康、能量水平和生活品質產生負面影響。

推動這一成長的關鍵因素是，越來越多的老年男性出現荷爾蒙變化，需要醫療干預。此外，醫療保健基礎設施和支持性監管框架的改善使得先進的治療方法更容易獲得。正在進行的研究和開發工作正在提高治療效果，確保更好的患者治療結果和長期遵守規定的治療方案。醫療保健提供者越來越關注治療睪固酮缺乏症的創新解決方案，導致全球治療採用率激增。

睾酮替代療法仍然是主要的治療方法，2024 年將產生 32 億美元的收入。隨著荷爾蒙療法的接受度不斷提高以及治療方案的更容易獲得，預計到 2034 年，這一領域的複合年成長率將達到 5.3%。睪固酮替代有助於恢復正常的荷爾蒙水平，改善性功能、肌肉量、情緒和整體健康。提供不同的給藥途徑，包括注射、外用凝膠和口服製劑，確保患者能夠選擇符合其生活方式和醫療需求的治療方法。優惠的報銷政策和保險覆蓋也在推動市場擴張方面發揮了關鍵作用，鼓勵製藥公司投資研究和創新。

根據給藥途徑，市場分為注射療法、外用療法和口服療法。注射睪固酮療法佔了 55.3% 的市場佔有率，到 2024 年將達到 22 億美元。這些療法因其能夠維持穩定的荷爾蒙水平，防止可能導致情緒波動、疲勞和性慾問題的波動而受到廣泛青睞。醫生青睞注射劑型，因為它們可以精確調整劑量，從而製定個性化的治療計劃，最佳化荷爾蒙水平，同時最大限度地減少潛在的副作用。因此，患者對這些療法的依從性仍然很高，進一步增強了市場成長。

北美繼續成為領先的區域市場，2024 年創造 18 億美元的收入，預計到 2034 年將達到 31 億美元。美國佔最大佔有率，2023 年貢獻了 16 億美元。患有荷爾蒙缺乏症的老齡男性數量不斷增加是該地區市場需求的主要驅動力。嚴格的監管標準確保了高品質、安全和有效的治療方法的可用性。此外，日益增多的宣傳活動、不斷增加的醫療保健支出以及醫學研究的進步都在支持市場擴張。隨著醫療保健提供者優先考慮以患者為中心的治療方法，創新療法和嚴格的品質控制措施將繼續塑造市場格局，確保受睪固酮缺乏症影響的個人獲得更好的治療效果。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 提高認知和診斷
    • 性腺功能低下發生率上升
    • 睾酮替代療法的進展
    • 男性健康和保健項目的成長
  • 產業陷阱與挑戰
    • 安全性問題和副作用
    • 嚴格遵守法規
• 成長潛力分析
• 監管格局
• 管道分析
• 差距分析
• 專利分析
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：依治療類型，2021 年至 2034 年

• 主要趨勢
• 睾酮替代療法
• 促性腺激素治療

第6章：市場估計與預測：依管理路線，2021 年至 2034 年

• 主要趨勢
• 注射劑
• 主題
• 口服

第7章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 卡爾曼症候群
• 克萊恩費爾特症候群
• 腦下垂體疾病
• 其他應用

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AbbVie
• Bayer
• Eli Lilly and Company
• Endo Pharmaceuticals
• Ferring Holdings
• Perrigo Company
• Pfizer
• Sanofi
• Teva Pharmaceutical Industries
• Viatris

The Global Male Hypogonadism Market was valued at USD 4 billion in 2024 and is projected to grow at a CAGR of 5.2% from 2025 to 2034. The growth is driven by increasing awareness of hormonal imbalances, advancements in diagnostic capabilities, and the rising prevalence of testosterone deficiency. This condition occurs when the body fails to produce adequate testosterone or when the testes do not function properly, leading to significant physical, sexual, and psychological complications. Since testosterone plays a crucial role in numerous male physiological functions, its deficiency can negatively impact overall health, energy levels, and quality of life.

A key factor fueling this growth is the increasing number of aging men experiencing hormonal changes that require medical intervention. Additionally, improved healthcare infrastructure and supportive regulatory frameworks are making advanced therapies more accessible. Ongoing research and development efforts are enhancing treatment efficacy, ensuring better patient outcomes and long-term adherence to prescribed therapies. Healthcare providers are increasingly focusing on innovative solutions to manage testosterone deficiency, leading to a surge in treatment adoption worldwide.

Testosterone replacement therapy remains the dominant treatment approach, generating USD 3.2 billion in revenue in 2024. This segment is expected to expand at a CAGR of 5.3% through 2034, supported by the growing acceptance of hormone therapy and easier access to treatment options. Testosterone replacement helps restore normal hormone levels, improving sexual function, muscle mass, mood, and overall well-being. The availability of different administration routes, including injectables, topical gels, and oral formulations, ensures that patients can choose a treatment that aligns with their lifestyle and medical needs. Favorable reimbursement policies and insurance coverage have also played a pivotal role in driving market expansion, encouraging pharmaceutical companies to invest in research and innovation.

Based on the route of administration, the market is segmented into injectable, topical, and oral therapies. Injectable testosterone therapies accounted for a 55.3% market share, reaching USD 2.2 billion in 2024. These treatments are widely preferred for their ability to maintain stable hormone levels, preventing fluctuations that could cause mood swings, fatigue, and libido issues. Physicians favor injectable formulations due to their precision in dosage adjustments, allowing for personalized treatment plans that optimize hormone levels while minimizing potential side effects. As a result, patient adherence to these therapies remains high, further strengthening market growth.

North America continues to be a leading regional market, generating USD 1.8 billion in revenue in 2024 and expected to reach USD 3.1 billion by 2034. The U.S. accounted for the largest share, contributing USD 1.6 billion in 2023. The rising number of aging men dealing with hormonal deficiencies is a major driver of market demand in this region. Strict regulatory standards ensure the availability of high-quality, safe, and effective therapies. Additionally, growing awareness campaigns, increased healthcare spending, and advancements in medical research are supporting market expansion. As healthcare providers prioritize patient-centric treatment approaches, innovative therapies and stringent quality control measures will continue to shape the market landscape, ensuring improved outcomes for individuals affected by testosterone deficiency.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing awareness and diagnosis
    • 3.2.1.2 Rising incidence of hypogonadism
    • 3.2.1.3 Advancements in testosterone replacement therapies
    • 3.2.1.4 Growth in men’s health and wellness programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Safety concerns and side effects
    • 3.2.2.2 Stringent regulatory compliance
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Gap analysis
• 3.7 Patent analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Testosterone replacement therapy
• 5.3 Gonadotropin therapy

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Injectable
• 6.3 Topical
• 6.4 Oral

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Kallmann syndrome
• 7.3 Klinefelter syndrome
• 7.4 Pituitary disorders
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Bayer
• 9.3 Eli Lilly and Company
• 9.4 Endo Pharmaceuticals
• 9.5 Ferring Holdings
• 9.6 Perrigo Company
• 9.7 Pfizer
• 9.8 Sanofi
• 9.9 Teva Pharmaceutical Industries
• 9.10 Viatris